Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PPM1B | O75688 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17328123 | 0.82 | HSD11B1 (0.35) | ALDH1A1GLAHPGDHTTMEN1 | |
| SCHEMBL21987198 | 0.73 | PPM1B (0.36) | ALDH1A1GLAHPGDHTTMEN1 | |
| SCHEMBL21944022 | 0.70 | PPM1B (0.39) | ALDH1A1GLAHPGDHTTMEN1 | |
| SCHEMBL14297372 | 0.70 | PPM1B (0.39) | ALDH1A1GLAHPGDHTTMEN1 | |
| SCHEMBL21396529 | 0.70 | CHRM2 (0.30) | MEN1KMT2APOLB | |
| SCHEMBL18951234 | 0.69 | — | — | |
| SCHEMBL14297376 | 0.68 | PPM1B (0.47) | ALDH1A1HTTMEN1KMT2APOLB | |
| SCHEMBL12732732 | 0.68 | PPM1B (0.43) | ALDH1A1GLAHPGDHTTMEN1 | |
| SCHEMBL24404660 | 0.66 | PPM1B (0.42) | ALDH1A1GLAHPGDHTTMEN1 | |
| SCHEMBL8144512 | 0.65 | CHRM2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | ALDH1A1 4081/4885GLA 788/4885HPGD 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.